Delta-like 1 homolog (DLK1) as a possible therapeutic target and its application to radioimmunotherapy using 125I-labelled anti-DLK1 antibody in lung cancer models (HOT1801 and FIGHT004)

Lung cancer is the most common cancer in the world today and is a leading cause of death due to cancer [1]. Non-small-cell lung cancer (NSCLC) accounts for approximately 80% of all cases of lung cancer. In developed countries, close to 70% of patients with NSCLC present with locally advanced or metastatic disease at the time of diagnosis, when curative treatment typically is no longer feasible [2]. Recently, new antineoplastic agents have been developed for the treatment of NSCLC by molecularly targeted therapies or immune checkpoint inhibitors (ICIs).

Source: Lung Cancer - January 13, 2021 Category: Cancer & Oncology Authors: Hironori Takagi, Songji Zhao, Satoshi Muto, Hiroshi Yokouchi, Hiroshi Nishihara, Toshiyuki Harada, Hikaru Yamaguchi, Hayato Mine, Masayuki Watanabe, Yuki Ozaki, Takuya Inoue, Takumi Yamaura, Mitsuro Fukuhara, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Source Type: research